Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU550486B2 - Antibodies having dual specificities, their preparation and uses therefor - Google Patents
[go: Go Back, main page]

AU550486B2 - Antibodies having dual specificities, their preparation and uses therefor - Google Patents

Antibodies having dual specificities, their preparation and uses therefor

Info

Publication number
AU550486B2
AU550486B2 AU15559/83A AU1555983A AU550486B2 AU 550486 B2 AU550486 B2 AU 550486B2 AU 15559/83 A AU15559/83 A AU 15559/83A AU 1555983 A AU1555983 A AU 1555983A AU 550486 B2 AU550486 B2 AU 550486B2
Authority
AU
Australia
Prior art keywords
antibodies
preparation
uses therefor
dual specificities
specificities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU15559/83A
Other versions
AU1555983A (en
Inventor
Thomas H. Adams
Richard M. Bartholomew
Gary S. David
James M. Frincke
Joanne Martinis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of AU1555983A publication Critical patent/AU1555983A/en
Application granted granted Critical
Publication of AU550486B2 publication Critical patent/AU550486B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU15559/83A 1982-04-12 1983-04-12 Antibodies having dual specificities, their preparation and uses therefor Expired AU550486B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12
US367784 1982-04-12

Publications (2)

Publication Number Publication Date
AU1555983A AU1555983A (en) 1983-11-04
AU550486B2 true AU550486B2 (en) 1986-03-20

Family

ID=23448582

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15559/83A Expired AU550486B2 (en) 1982-04-12 1983-04-12 Antibodies having dual specificities, their preparation and uses therefor

Country Status (11)

Country Link
EP (1) EP0105360A4 (en)
JP (2) JPH0753119B2 (en)
AT (1) AT394577B (en)
AU (1) AU550486B2 (en)
CA (1) CA1213229A (en)
CH (1) CH672796A5 (en)
ES (7) ES521370A0 (en)
FI (2) FI900212A7 (en)
GB (4) GB2128631B (en)
IT (1) IT1219778B (en)
WO (1) WO1983003679A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (en) * 1988-09-27 2001-06-18 武田薬品工業株式会社 Hybrid monoclonal antibodies, antibody-producing polydomas and antibody-containing drugs
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
CA1214123A (en) * 1983-01-20 1986-11-18 Masashi Matsui Cell lines for use in the preparation of hybridoma cells
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3583278D1 (en) * 1984-04-23 1991-07-25 Boston Biomed Res Inst DOUBLE SPECIFIC ANTIBODY DETERMINANTS.
NL8501219A (en) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic IMMUNOLOGICAL COMPLEX, ITS PREPARATION AND APPLICATION.
EP0241907A3 (en) 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
FR2604092B1 (en) * 1986-09-19 1990-04-13 Immunotech Sa IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
DE3850542T2 (en) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antibody heteroconjugates for killing HIV-infected cells.
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
JPH02196799A (en) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol Complex of anti-human cancer protein
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (en) * 1988-12-23 1992-06-30 Biodata Spa IMMUNOLOGICAL TEST FOR HOMOGENEOUS DETERMINATIONS
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (en) * 1989-09-21 1994-10-28 Immunotech Partners NOVEL HYDROPHILIC DERIVATIVES, APPLICATION TO DIAGNOSIS AND THERAPEUTICS, DIAGNOSTIC OR THERAPEUTIC KITS AND IMMUNOLOGICAL REAGENTS.
DE69130561T2 (en) * 1990-02-16 1999-06-24 Boston Biomedical Research Institute, Inc., Boston, Mass. Hybrid reagents with the ability to selectively release molecules into cells
TW212184B (en) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
CA2108451A1 (en) * 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
DK1545613T3 (en) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatin conjugates and their use in the treatment of cancer, an autoimmune disease or an infectious disease
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
KR101274524B1 (en) 2004-03-16 2013-06-19 온코노바 테라퓨틱스, 인코포레이티드 Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
JP5122441B2 (en) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド Humanized anti-CD70 binding agents and uses thereof
DK3248613T3 (en) 2005-07-18 2022-03-14 Seagen Inc BETA-GLUCURONIDE-MEDICINE-LINKER CONJUGATES
PT2099823E (en) 2006-12-01 2014-12-22 Seattle Genetics Inc Variant target binding agents and uses thereof
RU2474585C2 (en) 2007-01-22 2013-02-10 Дженентек, Инк. Precipitating and purifying proteins with polyelectrolytes
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
HK1220626A1 (en) 2013-03-15 2017-05-12 The Centre For Drug Research And Development Cytotoxic and anti-mitotic compounds, and methods of using the same
US10227407B2 (en) 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
ES2905569T3 (en) 2014-09-17 2022-04-11 Zymeworks Inc Cytotoxic and antimitotic compounds and methods of using them
CN107029242A (en) 2015-11-03 2017-08-11 财团法人工业技术研究院 Antibody drug complex and method for producing same
CN109843919A (en) 2016-03-25 2019-06-04 西雅图基因公司 The method for being used to prepare the agent-linker and its intermediate of Pegylation
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
KR102648564B1 (en) 2017-03-24 2024-03-19 씨젠 인크. Manufacturing process of glucuronide drug-linker and its intermediates
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
JP7156653B2 (en) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ Chimeric antigen receptor cells for treating solid tumors
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
IL287938B2 (en) 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody drug conjugates
TWI877278B (en) 2019-12-30 2025-03-21 美商思進公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Antibody drug conjugates
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
TW202317190A (en) 2021-06-29 2023-05-01 美商思進公司 Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
GB8530308D0 (en) 1986-01-22
GB2167086A (en) 1986-05-21
FI834529A0 (en) 1983-12-09
JPH0753600A (en) 1995-02-28
ES527963A0 (en) 1985-02-16
ES8606655A1 (en) 1986-04-01
JPS6312276A (en) 1988-01-19
EP0105360A1 (en) 1984-04-18
FI900212A0 (en) 1990-01-15
ES8607386A1 (en) 1986-05-16
ES538727A0 (en) 1986-02-01
GB2167086B (en) 1987-03-04
FI900212A7 (en) 1990-01-15
ES8603080A1 (en) 1985-12-01
GB2128631B (en) 1987-02-25
CH672796A5 (en) 1989-12-29
ES8506091A1 (en) 1985-06-16
ES8503441A1 (en) 1985-02-16
GB8332646D0 (en) 1984-01-11
ES533931A0 (en) 1985-06-16
GB2168998B (en) 1987-03-04
GB8530310D0 (en) 1986-01-22
GB2128631A (en) 1984-05-02
FI834529L (en) 1983-12-09
GB8530309D0 (en) 1986-01-22
ES545247A0 (en) 1986-05-16
GB2169921A (en) 1986-07-23
IT1219778B (en) 1990-05-24
ES537257A0 (en) 1986-04-01
ES8604424A1 (en) 1986-02-01
JPH0753119B2 (en) 1995-06-07
JP2562002B2 (en) 1996-12-11
ES533930A0 (en) 1985-12-01
EP0105360A4 (en) 1986-07-08
ES8504461A1 (en) 1985-04-16
IT8320548A0 (en) 1983-04-12
AT394577B (en) 1992-05-11
WO1983003679A1 (en) 1983-10-27
FI834529A7 (en) 1983-12-09
AU1555983A (en) 1983-11-04
GB2168998A (en) 1986-07-02
GB2169921B (en) 1987-03-04
CA1213229A (en) 1986-10-28
ATA901883A (en) 1991-10-15
ES521370A0 (en) 1985-04-16

Similar Documents

Publication Publication Date Title
AU550486B2 (en) Antibodies having dual specificities, their preparation and uses therefor
AU558258B2 (en) Immunogenic protein complex
AU4154385A (en) Antibodies, manufacture and use
AU4493685A (en) Polyclonal antibodies, preparation and use
AU537806B2 (en) Monoclonal antibody
AU2144083A (en) Boomerang
AU560305B2 (en) Plant-promoting preparations
AU554817B2 (en) Human immunoglobulin
AU3330689A (en) Monoclonal antibodies
AU557970B2 (en) Improved mycostatic whey and its manufacture
GB8416902D0 (en) Antibody preparations
AU553154B2 (en) Iron-selenium preparation
AU569816B2 (en) Monoclonal anti-alpha-amylase antibody
AU563881B2 (en) Carbacycline, preparation and utilization thereof
AU7165891A (en) Tumor-specific, cell surface-binding monoclonal antibodies
AU4174789A (en) Hybrid monoclonal antibodies, their production and use
IL69531A0 (en) Antibodies against bacterial peptidoglycans,their preparation and determination
AU6071780A (en) Antibody serum
AU565485B2 (en) Supported viral antigen
AU618720B2 (en) Monoclonal antibodies
AU555029B2 (en) Combined shampoo-conditioner
AU6639186A (en) Monoclonal antibodies to p. aeruginosa
AU556941B2 (en) Glycosidic linkage related antigen
AU612122C (en) Monoclonal antibodies
AU8003187A (en) Monoclonal antibodies

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired